9823 Capital’s Xeris Biopharma Holdings XERS Stock Holding History

9823 Capital’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,917	Closed	-$196K	–	84
2025 Q4	$196K	Buy	+24,917	New	+$196K	0.13%	41

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

9823 Capital's XERS Position: Q1 2026 in Review

9823 Capital sold out of Xeris Biopharma Holdings (XERS) in Q1 2026, closing a stake of 24,917 shares — an estimated $196K sold.

9823 Capital first reported a position in XERS in Q4 2025 and held it in 1 quarter. The position peaked at $196K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

9823 Capital reported no remaining Xeris Biopharma Holdings position as of Q1 2026 after selling out during the quarter.
9823 Capital sold 24,917 Xeris Biopharma Holdings shares in Q1 2026, an estimated $196K.
9823 Capital first reported a position in Xeris Biopharma Holdings in Q4 2025 and held it in 1 quarter.
9823 Capital's Xeris Biopharma Holdings position peaked at $196K in Q4 2025.
237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on 9823 Capital's 13F filing for Q1 2026, filed 15 May 2026.